NFE2L2 and non-small cell lung carcinoma: However, in Hellyer’ study, 7% (17 in 228) of EGFR‐mutant NSCLC patients also carried alterations in KEAP1/NFE2L2/CUL3, the patients with the comutation of KEAP1/NFE2L2/CUL3 had a shorter median time to treatment resistance on EGFR TKI (4.7 months) than the wild‐type matched cohort (13.0 months).34